No Data
cabio biotech(wuhan) (688089.SH): has not yet involved in NMN related technology and research
Glonghui, on November 19, announced that cabio biotech (wuhan) (688089.SH) stated on the interactive platform that the company uses synthetic biology as the underlying technology and cell factories as the preparation method, providing high-quality nutrient products and innovative solutions for clients in the global nutrition and health sectors through sustainable biomanufacturing. The main products currently include polyunsaturated fatty acids ARA, algal oil DHA, terpenoids β-carotene, astaxanthin, carbohydrate substances SA, and HMOs, widely used in infant formula, health foods, animal nutrition, personal care, and beauty fields, and based on synthesis.
Cabio Biotech (Wuhan) (688089.SH): Currently equipped with small AIGC for fine-tuning training.
Gallop meeting on November 19th: Cabio Biotech(Wuhan) (688089.SH) stated on the interactive platform that, regarding the application of artificial intelligence in research and development, the company has explored the fields of synthetic biology and artificial intelligence. Currently, it has a small AIGC that can be fine-tuned through training. It can be specifically applied to organizing experimental reports, initial design of technical solutions, construction of literature knowledge graphs, and monitoring of product information markets. This helps improve the efficiency and quality of research and development, promotes the intelligence and automation of scientific research work, and provides strong intellectual support for R&D activities.
cabio biotech(wuhan) (688089.SH): LNnT has completed small-scale trial fermentation process optimization and entered the pilot phase
gelonhui November 19th cabio biotech(wuhan) (688089.SH) stated on the interactive platform that the company has already developed a series of HMOs products including 2’-FL, 3-FL, 3’-SL, 6’-SL, LNnT, and related patents. According to the company's disclosed 2024 interim report, LNnT has completed small-scale fermentation process optimization and entered the pilot phase. Other company-related patents are not related to the company.
Jia Biyou: Jia Biyou Biotechnology (Wuhan) Co., Ltd. Report for the third quarter of 2024
Jiabiyou Biotechnology (Wuhan) Co., Ltd. Report for the third quarter of 2024
cabio biotech(wuhan) (688089.SH): Intends to plan the purchase of the controlling rights of Europe Easy, stocks suspended on October 29th.
Gelonghui on October 28th announced that Cabio Biotech (Wuhan) (688089.SH) is planning to acquire the controlling rights of EUYI through the issuance of shares and cash payment, while planning to raise matching funds. Preliminary calculations show that this trade is expected to constitute a major asset restructuring. After applying to the Shanghai Stock Exchange, the company's stocks will be suspended from trading starting on October 29, 2024 (Tuesday), with an expected suspension period of not more than 5 trading days.
